Photo of Grace F. Napolitano
D United States House · District 31 · Former member · California

Rep. Grace F. Napolitano

Compare
Total votes
2,168
all sessions
Attendance
97%
65 missed
Lower than 80% of chamber peers
With party
98%
of cast votes
Higher than 91% of chamber peers
Bipartisan score
1%
crosses aisle rarely
Lower than 90% of chamber peers
Sponsored
1,162
bills & resolutions
Near the chamber average
Committees
0
assignments
1,162 bills and resolutions

Sponsored bills

Total
1,162
Primary
29
Co-sponsor
1,133
This page
1,162
matching current filters
Co-sponsor HR 6385
In committee · United States House · Co-sponsor
Masks for All Act of 2022

Masks for All Act of 2022 This bill directs the Federal Emergency Management Agency (FEMA) to manufacture and distribute N-95 respirator masks to every individual in the United States and to provide N-95 masks to all individuals working in health care settings in the United States that are experiencing a shortage of such masks. FEMA must provide the masks at no cost to individuals and deliver them, to the greatest extent possible, using the U.S. Postal Service. Additionally, FEMA shall designate mask pickup sites in each community and shall provide masks to each site, allocated according to population; consider new designs for masks to improve comfort, fit, and size options; and submit to Congress a strategic plan that includes monthly, measurable targets to eliminate shortages and increase domestic production of N-95 masks and to fulfill all other requirements of this bill. The President shall make use of any and all available authorities (including emergency authorities) at the disposal of the federal government to procure and domestically manufacture N-95 masks and support the domestic manufacturing of N-95 masks.

In committee Jan 13, 2022 1 co-sponsor
Co-sponsor HR 6117
In committee · United States House · Co-sponsor
PrEP Access and Coverage Act

PrEP Access and Coverage Act This bill requires private health insurance plans to cover prescription drugs that prevent HIV, including related screenings, diagnostic procedures, administrative fees, and clinical follow-ups, without any cost-sharing obligation for the plan holder. Further, insurance plans must not impose any preauthorization requirement for this coverage. These coverage requirements also apply to public health insurance programs, including Medicare, Medicaid, and the Children's Health Insurance Program. Additionally, the bill prohibits denying, limiting, or qualifying coverage or increasing premiums for disability insurance, long-term care insurance, or life insurance policies based on an individual taking medication for HIV prevention. The bill further requires the Department of Health and Human Services to award grants to states, or directly to eligible local organizations, to provide uninsured individuals and underinsured individuals access to prescription drugs and related services that prevent HIV. The Centers for Disease Control and Prevention also must develop a public awareness campaign that focuses efforts in communities with a high need for HIV prevention treatment.

In committee Jan 6, 2022 1 co-sponsor
Co-sponsor HR 3537
Signed into law · United States House · Co-sponsor
Accelerating Access to Critical Therapies for ALS Act

Accelerating Access to Critical Therapies for ALS Act This bill establishes grant programs to address neurodegenerative diseases, such as amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease), and contains other related provisions. The Department of Health and Human Services (HHS) shall award grants to eligible entities for scientific research utilizing data from expanded access to investigational ALS treatments for individuals who are not otherwise eligible for clinical trials.  The Food and Drug Administration (FDA) shall award grants to public and private entities to cover the costs of research and development of drugs that diagnose or treat ALS and other rare neurodegenerative diseases. HHS shall also establish the Public-Private Partnership for Neurodegenerative Diseases between the National Institutes of Health, the FDA, and at least one eligible entity (generally, an institution of higher education or a nonprofit organization). The partnership shall support the development and regulatory review of drugs that address ALS and other rare neurodegenerative diseases. The FDA shall publish on its website a five-year action plan for fostering the development of drugs that improve or extend the lives of people living with rare neurodegenerative diseases. The Government Accountability Office must report to Congress about the grants provided under this bill, including an analysis of the impact of such grants on research and development of treatments for ALS.

Signed into law Dec 23, 2021 1 co-sponsor
Co-sponsor HCONRES 66
In committee · United States House · Co-sponsor
Recognizing international days of peace, coexistence, and cooperation.

This resolution recognizes the anniversaries of the International Day of Peace, Human Solidarity Day, the International Day of Living Together in Peace, and other specified international days. The resolution also expresses that Congress commits to (1) encouraging the people of the United States to continue commemorating international days of peace, coexistence, and cooperation; and (2) supporting activities on such days that promote thoughtful, deliberative, and cooperative actions to achieve peace.

In committee Dec 20, 2021 1 co-sponsor
Co-sponsor HR 6168
In committee · United States House · Co-sponsor
Future Generations Protection Act

Future Generations Protection Act This bill prohibits (1) the emission of any greenhouse gas in any quantity from a new electric utility steam generating unit (i.e., certain power plants); (2) hydraulic fracturing on all onshore and offshore land in the United States; and (3) exports of domestically produced crude oil and natural gas, with specified exceptions.

In committee Dec 17, 2021 1 co-sponsor
Co-sponsor HR 5314
Passed · United States House · Co-sponsor
Protecting Our Democracy Act

Protecting Our Democracy Act This bill addresses issues involving (1) abuses of presidential power; (2) checks and balances, accountability, and transparency; and (3) election integrity and security. Specifically, regarding abuses of presidential power, the bill requires the Department of Justice (DOJ) and the President to submit to Congress specified materials relating to certain pardons, prohibits presidential self-pardons, suspends the statute of limitations for federal offenses committed by a sitting President or Vice President, prohibits the acceptance of foreign or domestic emoluments, and sets forth provisions regarding Office of Government Ethics and Office of Special Counsel jurisdiction and enforcement authority. To address checks and balances, accountability, and transparency, the bill authorizes specified actions to enforce congressional subpoenas, imposes limits on presidential declarations of emergencies, requires DOJ to maintain a log of specified communications between it and the White House, requires cause for removal of inspectors general, increases whistleblower protections, and requires a candidate for President or Vice President to provide copies of tax returns for the 10 most recent taxable years to the Federal Election Commission. To address election integrity and security, the bill requires federal campaign reporting of foreign contacts, makes various changes to requirements concerning foreign donations to political campaigns and candidates and foreign contributions to online electioneering communications, prohibits distribution of materially deceptive audio or visual media prior to an election (i.e., deepfakes), and establishes a program to support states and localities transition to ranked choice voting systems.

Passed Dec 13, 2021 1 co-sponsor
Co-sponsor HR 6207
In committee · United States House · Co-sponsor
Humane Cosmetics Act of 2021

Humane Cosmetics Act of 2021 This bill generally prohibits animal testing in the evaluation of cosmetic products, and it prohibits the sale or transport of cosmetics developed using animal testing, subject to civil penalties. These prohibitions begin one year after enactment. The bill specifies exceptions to these prohibitions, including if such animal testing (1) is conducted outside the United States to comply with a foreign regulatory authority; (2) is pursuant to a specified finding that there are no nonanimal alternatives to test the safety of a potentially dangerous cosmetic product or ingredient; (3) is of a product or ingredient for a drug or device subject to regulation by the Food and Drug Administration (FDA); or (4) is required for a noncosmetic purpose pursuant to a state, federal, or foreign regulatory authority. Further, no animal-testing evidence may be used to establish the safety of a cosmetic product or ingredient that is regulated by the FDA after the effective date of this bill, subject to limited exceptions.

In committee Dec 10, 2021 1 co-sponsor
Showing 691 to 700 of 1,162 bills
Previous 1 … 69 70 71 … 117 Next